Comparison of Visual Outcome and Regression Pattern of Myopic Choroidal Neovascularization After Intravitreal Bevacizumab or After Photodynamic Therapy

American Journal of Ophthalmology

Volumn 148, Issue 3, 2009, Pages

  Hayashi, Kengo ^a   Ohno Matsui, Kyoko ^a   Teramukai, Satoshi ^b   Shimada, Noriaki ^a   Moriyama, Muka ^a   Hayashi, Wakako ^a   Yoshida, Takeshi ^a   Tokoro, Takashi ^a   Mochizuki, Manabu ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; VERTEPORFIN;

ADULT; AGED; ARTICLE; CASE STUDY; CHORIORETINOPATHY; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MYOPIA; OPEN STUDY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REMISSION; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 68949107609     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2009.03.026     Document Type: Article

References (29)

1. Cohen S.Y., Larosche A., Leguen Y., et al. Etiology of choroidal neovascularization in young patients. Ophthalmology 103 (1996) 1241-1244
2. Yoshida T., Ohno-Matsui K., Yasuzumi K., et al. Myopic choroidal neovascularization. A 10-year follow-up. Ophthalmology 110 (2003) 1297-1305
3. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial-VIP Report No. 1. Ophthalmology 108 (2001) 841-852
4. Blinder K.J., Blumenkranz M.S., Bressler N.M., et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: two-year results of a randomized clinical trial-VIP Report No. 3. Ophthalmology 110 (2003) 667-673
5. Ikuno Y., Sayanagi K., Soga K., et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 147 (2009) 94-100
6. Gharbiya M., Allievi F., Mazzeo L., and Gabrieli C.B. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 147 (2009) 84-93
7. Chan W.M., Lai T.Y.Y., Liu D.T.L., and Lam D.S.C. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: 1-year results of a prospective study. Br J Ophthalmol 93 (2009) 150-154
8. Sakaguchi H., Ikuno Y., Gomi F., et al. Intravitreal injection of bevacizumab for choroidal neovascularization associated with pathological myopia. Br J Ophthalmol 91 (2007) 161-165
9. Yamamoto I., Rogers A.H., Reichel E., et al. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularization secondary to pathological myopia. Br J Ophthalmol 91 (2007) 157-160
10. Chan W.M., Lai T.Y.Y., Liu D.T.L., and Lam D.S.C. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology 114 (2007) 2190-2196
11. Mandal S., Venkatesh P., Sampangi R., and Garg S. Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization. Eur J Ophthalmol 17 (2007) 620-626
12. Rensch F., Spandau U.H., Schlichtenbreds F., et al. Intravitreal bevacizumab for myopic choroidal neovascularization. Ophthalmic Surg Lasers Imaging 39 (2008) 182-185
13. Chang L.K., Spaide R.F., Brue C., et al. Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration. Arch Ophthalmol 126 (2008) 941-945
14. Arias L., Planas N., Prades S., et al. Intravitreal bevacizumab (Avastin) for choroidal neovascularization secondary to pathological myopia: 6-month results. Br J Ophthalmol 92 (2008) 1035-1039
15. Tewari A., Dhala M.S., and Apte R.S. Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia. Retina 26 (2006) 1093-1094
16. Laud K., Spaide R.F., Freund K.B., et al. Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 26 (2006) 960-963
17. Blaauwgeers H.G., Holtkamp G.M., Rutten H., et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol 155 (1999) 421-428
18. Saint-Geniez M., Maldonado A.E., and D'Amore P.A. VEGF expression and receptor activation in the choroid during development and in the adult. Invest Ophthalmol Vis Sci 47 (2006) 3135-3142
19. Yourey P.A., Gohari S., Su J.L., and Alderson R.F. Vascular endothelial growth factors promote the in vitro development of rat photoreceptor cells. J Neurosci 20 (2000) 6781-6788
20. Gora-Kupilas K., and Josko J. The neuroprotective function of vascular endothelial growth factor (VEGF). Folia Neuropathol 43 (2005) 31-39
21. Jin K.L., Mao X.O., and Greenberg D.A. Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc Natl Acad Sci U S A 97 (2000) 10242-10247
22. Hayashi K., Ohno-Matsui K., Teramukai S., et al. Photodynamic therapy with verteporfin for choroidal neovascularization of pathologic myopia in Japanese patients: comparison with nontreated controls. Am J Ophthalmol 145 (2008) 518-526
23. Ohno-Matsui K., Morishima N., Ito M., and Tokoro T. Indocyanine green angiographic findings of lacquer cracks in pathologic myopia. Jpn J Ophthalmol 42 (1998) 293-299
24. Ikuno Y., Sayanagi K., Soga K., et al. Lacquer crack formation and choroidal neovascularization in pathologic myopia. Retina 28 (2008) 1124-1131
25. TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of two randomized clinical trials-TAP Report No. 2. Arch Ophthalmol 119 (2001) 198-207
26. Zhu Q., Ziemssen F., Henke-Fahle S., et al. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 115 (2008) 1750-1755
27. Schmidt-Erfurth U., Niemeyer M., Geitzenauer W., and Michels S. Time course and morphology of vascular effects associated with photodynamic therapy. Ophthalmology 112 (2005) 2061-2069
28. Postelmans L., Pasteels B., Coquelet P., et al. Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females. Am J Ophthalmol 138 (2004) 803-808
29. Ohno-Matsui K., Moriyama M., Hayashi K., and Mochizuki M. Choroidal vein and artery occlusion following photodynamic therapy in eyes with pathologic myopia. Graefes Arch Clin Exp Ophthalmol 244 (2006) 1363-1366